The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.
Richard D. Carvajal
Research Funding - MabVax
Rashmi Chugh
Research Funding - MabVax
Mohammed M. Milhem
Research Funding - MabVax
Christopher W. Ryan
Research Funding - MabVax
Suzanne George
Research Funding - MabVax
Bartosz Chmielowski
Research Funding - MabVax
Mark Agulnik
Research Funding - MabVax
Eve T. Rodler
Research Funding - MabVax
Anthony D. Elias
Research Funding - MabVax
G. Thomas Budd
Research Funding - MabVax
Hussein Tawbi
Research Funding - MabVax
Sujana Movva
Research Funding - MabVax
Brian Andrew Van Tine
Research Funding - MabVax
Mark Andrew Dickson
No relevant relationships to disclose
Martee Leigh Hensley
No relevant relationships to disclose
Mary Louise Keohan
No relevant relationships to disclose
William D. Tap
No relevant relationships to disclose
Cathryn M. Bennett
Employment or Leadership Position - MabVax
Robert G. Maki
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose